Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years Presented ByMs Amanda C. Miles, Pfizer Inc., NY, USA ConferenceESCMID Vaccines 2025 TypePeer-reviewed article 21 October 2025 14:39